Human CD253 ELISA Kit
Product Specifications
- Catalogue N°
- 850.770.048 - 1 x 48 Discovery (pre-coated)
850.770.096 - 1 x 96 (pre-coated)
850.770.192 - 2 x 96 (pre-coated) - Assay Range
- 93.75 pg/ml - 3000 pg/ml
- Sensitivity
- 64 pg/ml
- Target species
- Human
- Specificity
- Recognizes both natural and recombinant soluble human Trail
- Incubation
- 3h45
- Sample Type
- Serum, Plasma, Cell culture supernatant
- Sample Size
- 100 µl
- Cross Reaction
- No cross reactivity with other human soluble molecules
- Kit Content
- Diaclone ELISA Kits include pre-coated strip plates, biotinylated secondary antibody, standards, controls (where applicable), buffers, streptavidin-HRP, TMB, stop reagents and a detailed procedure.
- Synonym
- APO2L
References
- Wegrzynowska, M. et al., Poster Session 3 Europace 13 (suppl_3): 10.1093/europace/eur229
- Yalcin, A. D. et al.,World Allergy Organization Journal,2015; 8(1): 1-1
- Yalcin, A. D. et al.,World Allergy Organization Journal,2013; 6(1): 1-2
- Arik, H. O. et al.,Med Sci Monit.,2013; 19: 712-5 - Pubmed link
- Audige, A. et al., J Immunol.,2006; 177(9): 6227-37. - Pubmed link
- Audo, R. et al., Arthritis Res Ther.,2015; 17: 193 - Pubmed link
- Barblu, L. and J. P. Herbeuval,PLoS One,2012;7(3): e32874 - Pubmed link
- Bisgin, A. et al.,BMC Cancer,2012;12:58 - Pubmed link
- Bremer E. et al., Cancer Res., 2005; 65(8): 3380 - 3388 - Pubmed link
- Cassatella, M. A. et al., J Leukoc Biol., 2006; 79(1): 123-32. - Pubmed link
- Castellino, G. et al., Lupus,2007; 16(7): 479-482. - Pubmed link
- Celik, B. et al.,Med Sci Monit.,2013;19: 875-82 - Pubmed link
- Chehimi, J. et al.,J. Virol.,2010; 84(6): 2762-2773 - Pubmed link
- de Bruyn, M et al., Clin. Cancer Res., 2011; 17: 5626 - 5637 - Pubmed link
- French, M. A. et al.,J Infect Dis.,2009; 200(8):1212-5 - Pubmed link
- Gasper-Smith, N. et al., J. Virol.,2008; 82:7700-7710. - Pubmed link
- Ghorbel, M. T. et al., J. Thorac. Cardiovasc. Surg., 2010; 140(2): 337-345 - Pubmed link
- Han, L. H. et al., World J Gastroenterol.,2002;8 (6): 1077-80 - Pubmed link
- Herbeuval J-P. et al., Blood, 2005; 105(6): 2458 - 2464 - Pubmed link
- Herbeuval, J. P. et al., J Natl Cancer Inst .,2003;95(8): 611-21. - Pubmed link
- Indraccolo, S. et al., J Immunol.,2007; 178(2): 1122-35. - Pubmed link
- Jungel, A. et al., Ann Rheum Dis.,2006; 65(7): 910-2. - Pubmed link
- Kazimirsky, G. et al. , Stem Cell Res Ther.,2016; 7(1): 149. - Pubmed link
- Koga Y. et al., Cancer Res., 2004; 64(3): 1037 - 1043 - Pubmed link
- Laforge, M. et al., PLoS Pathog.,2011; 7(6): e1002087. - Pubmed link
- Lub-de Hooge M.N. et al., Ann. Rheum. Dis, 2005; 64(6): 854 - 858 - Pubmed link
- Lub-De Hooge M.N., Shock, 2004; 22(2): 186 - 188 - Pubmed link
- Ludwig A.T. et al., Cancer Res., 2004; 64(10): 3386 - 3390 - Pubmed link
- Lünemann JD. et al., J. Immunol., 2002; 168(10): 4881 - 4888 - Pubmed link
- Melki, M. T. et al., PLoS Pathog.,2010; 6(4): e1000862. - Pubmed link
- Merino, D. et al., Mol Cell Biol., 2006; 26(19): 7046-55. - Pubmed link
- Mielczarek-Palacz, A. et al.,Arch Med Sci. 2017 Apr 1;13(3):624-628. - Pubmed link
- Nguyen, V. et al., Clin Immunol.,2009; 132(1): 32-42. - Pubmed link
- Pelli, N. et al., Clin Exp Immunol.,2007;148(1): 85-9 - Pubmed link
- Plissonnier, M.L. et al.,Oncotarget, 2017; Nov 22;8(64):107744-107762 - Pubmed link
- Potu, H. et al.,Cancer Res.,2010;70(2): 655-665 - Pubmed link
- Prinz-Hadad, H. et al., J Neuroinflammation,2013; 10: 36 - Pubmed link
- Sabour Alaoui, S. et al.,PLoS One,2012; 7(3): e33609 - Pubmed link
- Saidi, H. et al., PLoS Pathog.,2016;12(2):e1005407 - Pubmed link
- Seyman, D. et al.,Int J Clin Exp Med.,2014; 7(12): 5650-6 - Pubmed link
- Simons, M. P. et al., Infect Immun.,2007; 75(3): 1265-71 - Pubmed link
- Tecchio C. et al., Blood, 2004; 103(10): 3837 - 3844 - Pubmed link
- Toriyama, S. et al., Mol. Cancer Ther.,2016;15(9):2066-2075 - Pubmed link
- Vermot-Desroches C. et al., Cell Immunol., 2005;236(1-2):86-91 - Pubmed link
- Wandinger KP et al., Lancet, 2003; 361(9374) : 2036 - 2043 - Pubmed link
- Yalcin, A. D. et al.,Med Sci Monit.,2012; 18(10): CR617-21 - Pubmed link
- Yalcin, A. D. et al.,Med Sci Monit.,2012; 18(3): PI11-5 - Pubmed link
- Yang, L. et al., Blood,2010; 116(20): 4307-4316 - Pubmed link
- Herbeuval, J. P. et al., AIDS. 2009 Jan 2; 23(1): 35–40. - Pubmed link
- Mielczarek-Palacz, M. et al., Cells. 2020 Mar; 9(3): 612. - Pubmed link
Related products
- 853.080.000 - Anti-Human CD253 Azide Free
- 853.082.010 - Anti-Human CD253 PE Conjugated
- 853.083.020 - Anti-Human CD253 Unconjugated
- 853.084.010 - Anti-Human CD253 Biotinylated
- 853.090.000 - Anti-Human CD253 Azide Free
- 879.770.001 - Anti-Human CD253 Capture Antibody
- 879.770.002 - Anti-Human CD253 Detection Antibody
BACKGROUND
TRAIL, TNF-Related Apoptosis-Inducing Ligand (TRAIL), is a member of the tumor necrosis factor (TNF) family, also designated as Apo-2 ligand (Apo-2L) and CD253. TRAIL is a 281-amino acid protein, related most closely to Fas/Apo-1 ligand. It is expressed at cell surface as a transmembrane protein with an extracellular region and a homotrimeric subunit structure and also exists as a soluble form
TRAIL interacts with several receptors: two pro-apoptotic death receptors DR4 (TRAIL R1) and DR5 (TRAIL R2) and three anti-apoptotic decoy receptors DcR1 (TRAIL R3), DcR2 (TRAIL R4) and osteoprotegrin (OPG). Soluble TRAIL induces apoptosis through these death receptors in many transformed cells (lymphoid as well as non-lymphoid tumor cell lines).
Because of its role in apoptosis and its stable trimer, TRAIL was described as a potential tumor-specific cancer therapeutic.
Version 22 - 11.21
For research use only
For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.